Lerman C - Search Results

1

Gender-stratified gene and gene-treatment interactions in smoking cessation.

Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, Tyndale RF, Benowitz NL, Lerman C, Conti DV. Lee W, et al. Among authors: lerman c. Pharmacogenomics J. 2012 Dec;12(6):521-32. doi: 10.1038/tpj.2011.30. Epub 2011 Aug 2. Pharmacogenomics J. 2012. PMID: 21808284 Free PMC article.

2

Non-replication of genetic association studies: is DAT all, folks?

Lerman C, Swan GE. Lerman C, et al. Nicotine Tob Res. 2002 Aug;4(3):247-9. doi: 10.1080/14622200210141220. Nicotine Tob Res. 2002. PMID: 12215232 No abstract available.

3

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.

Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Miksys S, et al. Among authors: lerman c. Neuropharmacology. 2003 Jul;45(1):122-32. doi: 10.1016/s0028-3908(03)00136-9. Neuropharmacology. 2003. PMID: 12814665

4

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.

Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH. Lerman C, et al. Pharmacogenomics J. 2004;4(3):184-92. doi: 10.1038/sj.tpj.6500238. Pharmacogenomics J. 2004. PMID: 15007373 Clinical Trial.

5

Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial.

Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, Benowitz N. Lerman C, et al. Ann Intern Med. 2004 Mar 16;140(6):426-33. doi: 10.7326/0003-4819-140-6-200403160-00009. Ann Intern Med. 2004. PMID: 15023708 Clinical Trial.

6

Genetics and drug use as a complex phenotype.

Lessov CN, Swan GE, Ring HZ, Khroyan TV, Lerman C. Lessov CN, et al. Among authors: lerman c. Subst Use Misuse. 2004;39(10-12):1515-69. doi: 10.1081/ja-200033202. Subst Use Misuse. 2004. PMID: 15587945 Review.

7

Smoking cessation treatment: pharmacogenetic assessment.

Munafò MR, Lerman C, Niaura R, Shields AE, Swan GE. Munafò MR, et al. Among authors: lerman c. Curr Opin Mol Ther. 2005 Jun;7(3):202-8. Curr Opin Mol Ther. 2005. PMID: 15977416 Review.

8

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.

Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Malaiyandi V, et al. Among authors: lerman c. Mol Psychiatry. 2006 Apr;11(4):400-9. doi: 10.1038/sj.mp.4001794. Mol Psychiatry. 2006. PMID: 16402128 Clinical Trial.

9

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Lerman C, et al. Clin Pharmacol Ther. 2006 Jun;79(6):600-8. doi: 10.1016/j.clpt.2006.02.006. Epub 2006 May 11. Clin Pharmacol Ther. 2006. PMID: 16765148 Clinical Trial.

10

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF. Lee AM, et al. Among authors: lerman c. Biol Psychiatry. 2007 Sep 15;62(6):635-41. doi: 10.1016/j.biopsych.2006.10.005. Epub 2007 Jan 16. Biol Psychiatry. 2007. PMID: 17223085 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

433 results

Search Page

Filters